NCT05487950View on ClinicalTrials.gov

Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

550

Participants

Timeline

Start Date

April 5, 2023

Primary Completion Date

April 5, 2027

Study Completion Date

April 5, 2027

Conditions

Excessive Supraventricular Ectopies or Short Atrial Runs (ESVEA)

Interventions

DRUG

Rivaroxaban group

Patients assigned in the Rivaroxaban group will receive 15 mg once day or 10 mg if dosage modification is needed due to renal insufficiency (Creatinine clairance calculated with the Cockroft formula between 30 or 49 ml/min).

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT05487950 - Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk | Biotech Hunter | Biotech Hunter